Evaluating Physician and Payer Perspectives in the Management of Hemophilia A

Russell P. Gollard, MD, FACP, discusses hemophilia patients in their plan, identifying these patients, and treatment with newer monoclonal factor products.

Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence.

Russell P. Gollard, MD, FACP, analyzes the role of ICER reports in optimizing patient care and health care costs.

Russell P. Gollard, MD, FACP, discusses ways to ensure access to appropriate treatment for rare diseases like hemophilia A, such as finding motivated providers with expertise and using utilization management strategies for cutting-edge care to bridge the gap between available community treatments and emerging therapies, ultimately benefiting patients.

Russell P. Gollard, MD, FACP, discusses how the rising costs of managing hemophilia A are influenced by drug expenses, treatment efficacy, and adverse events, creating significant financial burdens across health care settings and patient populations.

Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A.